Does THIOTEPA Cause Second primary malignancy? 46 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 46 reports of Second primary malignancy have been filed in association with THIOTEPA (Thiotepa). This represents 0.7% of all adverse event reports for THIOTEPA.
46
Reports of Second primary malignancy with THIOTEPA
0.7%
of all THIOTEPA reports
11
Deaths
10
Hospitalizations
How Dangerous Is Second primary malignancy From THIOTEPA?
Of the 46 reports, 11 (23.9%) resulted in death, 10 (21.7%) required hospitalization, and 3 (6.5%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for THIOTEPA. However, 46 reports have been filed with the FAERS database.
What Other Side Effects Does THIOTEPA Cause?
Off label use (762)
Febrile neutropenia (645)
Mucosal inflammation (616)
Cytomegalovirus infection (446)
Product use in unapproved indication (425)
Pyrexia (359)
Drug ineffective (358)
Acute graft versus host disease in skin (355)
Acute graft versus host disease (331)
Cytomegalovirus infection reactivation (325)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which THIOTEPA Alternatives Have Lower Second primary malignancy Risk?
THIOTEPA vs THIOTHIXENE
THIOTEPA vs THROMBIN
THIOTEPA vs THROMBIN HUMAN
THIOTEPA vs THYMOCYTE IMMUNE GLOBULIN NOS
THIOTEPA vs THYMOGLOBULINE